Neurolief, a developer of digital therapeutics brain neuromodulation technology, has announced that it has received the CE mark for its Relivion non-invasive, adaptive digital treatment for migraine. The CE mark allows Neurolief to market, sell and distribute the Relivion device as an over-the-counter therapy within the European Union and countries that participate with Agreements on Mutual … Continue reading The first non-invasive, adaptive neuromodulation digital treatment for migraine receives CE mark